156 related articles for article (PubMed ID: 9822920)
21. Combination with CK19 Might Increase the Prognostic Power of Hep Par 1 in Hepatocellular Carcinoma after Curative Resection.
Jin Y; Liang ZY; Zhou WX; Zhou L
J Invest Surg; 2018 Oct; 31(5):412-419. PubMed ID: 28758812
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7.
Ramos-Vara JA; Miller MA; Johnson GC
Vet Pathol; 2001 Nov; 38(6):636-43. PubMed ID: 11732796
[TBL] [Abstract][Full Text] [Related]
23. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.
Tsuji M; Kashihara T; Terada N; Mori H
Pathol Int; 1999 Apr; 49(4):310-7. PubMed ID: 10365850
[TBL] [Abstract][Full Text] [Related]
24. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases.
Terracciano LM; Glatz K; Mhawech P; Vasei M; Lehmann FS; Vecchione R; Tornillo L
Am J Surg Pathol; 2003 Oct; 27(10):1302-12. PubMed ID: 14508391
[TBL] [Abstract][Full Text] [Related]
25. Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study.
Tickoo SK; Zee SY; Obiekwe S; Xiao H; Koea J; Robiou C; Blumgart LH; Jarnagin W; Ladanyi M; Klimstra DS
Am J Surg Pathol; 2002 Aug; 26(8):989-97. PubMed ID: 12170085
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of expressions of Arg-1, Hep Par-1, and CK19 in the diagnosis of the primary hepatocellular carcinoma subtypes and exclusion of the metastases.
Atta IS
Histol Histopathol; 2021 Sep; 36(9):981-993. PubMed ID: 34254284
[TBL] [Abstract][Full Text] [Related]
27. Cytokeratin 20-positive hepatocellular carcinoma.
Fanni D; Nemolato S; Ganga R; Senes G; Gerosa C; Van Eyken P; Geboes K; Faa G
Eur J Histochem; 2009 Dec; 53(4):e32. PubMed ID: 22073364
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical detection of breast specific antigens and cytokeratins in metastatic breast carcinoma in the liver.
Akasofu M; Kawahara E; Kurumaya H; Nakanishi I
Acta Pathol Jpn; 1993 Dec; 43(12):736-44. PubMed ID: 7509105
[TBL] [Abstract][Full Text] [Related]
29. Combined fibrolamellar carcinoma and cholangiocarcinoma exhibiting biphenotypic antigen expression: a case report.
Tanaka K; Honna T; Kitano Y; Kuroda T; Tanaka K; Morikawa N; Matsuda H; Kawashima N; Matsuoka K; Miyauchi J
J Clin Pathol; 2005 Aug; 58(8):884-7. PubMed ID: 16049296
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
Dong H; Cong WL; Zhu ZZ; Wang B; Xian ZH; Yu H
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
[TBL] [Abstract][Full Text] [Related]
31. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.
Xiao SY; Wang HL; Hart J; Fleming D; Beard MR
Am J Pathol; 2001 Oct; 159(4):1415-21. PubMed ID: 11583969
[TBL] [Abstract][Full Text] [Related]
32. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
[TBL] [Abstract][Full Text] [Related]
33. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.
Fu X; Tan L; Liu S; Li H; Chen L; Qin J; Wu M; Wang H
J Cancer Res Clin Oncol; 2004 Sep; 130(9):514-20. PubMed ID: 15221469
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan.
Tomimatsu M; Ishiguro N; Taniai M; Okuda H; Saito A; Obata H; Yamamoto M; Takasaki K; Nakano M
Cancer; 1993 Aug; 72(3):683-8. PubMed ID: 8192727
[TBL] [Abstract][Full Text] [Related]
35. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers.
Proca DM; Niemann TH; Porcell AI; DeYoung BR
Appl Immunohistochem Mol Morphol; 2000 Jun; 8(2):120-5. PubMed ID: 10937059
[TBL] [Abstract][Full Text] [Related]
36. The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver.
Nash JW; Morrison C; Frankel WL
Arch Pathol Lab Med; 2003 Dec; 127(12):1591-5. PubMed ID: 14632573
[TBL] [Abstract][Full Text] [Related]
37. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis.
Rullier A; Le Bail B; Fawaz R; Blanc JF; Saric J; Bioulac-Sage P
Am J Surg Pathol; 2000 Jun; 24(6):870-6. PubMed ID: 10843291
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic significance of aquaporin-1 in liver tumors.
Mazal PR; Susani M; Wrba F; Haitel A
Hum Pathol; 2005 Nov; 36(11):1226-31. PubMed ID: 16260277
[TBL] [Abstract][Full Text] [Related]
39. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls.
Geramizadeh B; Boub R; Rahsaz M
Indian J Pathol Microbiol; 2007 Jul; 50(3):507-10. PubMed ID: 17883119
[TBL] [Abstract][Full Text] [Related]
40. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver.
Morrison C; Marsh W; Frankel WL
Mod Pathol; 2002 Dec; 15(12):1279-87. PubMed ID: 12481008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
